{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:39:20Z","timestamp":1788536360510,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1124\/dmd.112.050732","type":"journal-article","created":{"date-parts":[[2013,4,13]],"date-time":"2013-04-13T01:38:38Z","timestamp":1365817118000},"page":"1329-1338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole"],"prefix":"10.1016","volume":"41","author":[{"given":"Bing","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Y","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.050732_bib1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/dmd.105.008730","article-title":"Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole","volume":"34","author":"Chien","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050732_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050732_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib4","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions.","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.050732_bib5","unstructured":"FDA (2012) Drug Interaction Studies \u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http:\/\/wwwfdagov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362pdf"},{"key":"10.1124\/dmd.112.050732_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1007550717526","article-title":"Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells","volume":"17","author":"Gibbs","year":"2000","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.112.050732_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.bjc.6600123","article-title":"Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours","volume":"86","author":"Goh","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.112.050732_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2125.2010.03799.x","article-title":"Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models","volume":"71","author":"Guest","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinthera.2009.02.022","article-title":"Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers","volume":"31","author":"Krishna","year":"2009","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.112.050732_bib10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mcp.2002.129068","article-title":"Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping","volume":"72","author":"Lee","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050732_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/00912709922012015","article-title":"Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity","volume":"39","author":"McCrea","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","article-title":"General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs","volume":"46","author":"Ohno","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.112.050732_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050732_bib15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1124\/dmd.112.044602","article-title":"Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development","volume":"40","author":"Peters","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.050732_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.ftd.0000194497.55269.d9","article-title":"Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug","volume":"28","author":"Tham","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.112.050732_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.050732_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/0091270012439208","article-title":"Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations","author":"Yang","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0598-1","article-title":"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers","volume":"62","author":"Yong","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2007.03070.x","article-title":"Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction","volume":"65","author":"Youdim","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.050732_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270008331196","article-title":"Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study","volume":"49","author":"Zhao","year":"2009","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.050732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:09:19Z","timestamp":1739905759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624097435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0090955624097435"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.050732","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.050732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}